Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 12/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.59 |
| ▸ | AURKA | O14965 | 4/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.58 |
| ▸ | SRC | P12931 | 11/20 | 0.56 |
| ▸ | LCK | P06239 | 9/20 | 0.55 |
| ▸ | FYN | P06241 | 9/20 | 0.55 |
| ▸ | YES1 | P07947 | 9/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408966 | 1.00 | MET (0.64) | METKDRFGFR1PDGFRBAURKA | |
| SCHEMBL5407095 | 0.90 | MET (0.59) | METKDRFGFR1PDGFRBAURKA | |
| SCHEMBL5410960 | 0.88 | MET (0.64) | METKDRFGFR1PDGFRBAURKA | |
| SCHEMBL5417536 | 0.88 | MET (0.61) | METKDRFGFR1PDGFRBAURKA | |
| SCHEMBL5396583 | 0.87 | SRC (0.74) | KDRFGFR1PDGFRBAURKAAURKB | |
| SCHEMBL5410896 | 0.85 | SRC (0.62) | METKDRFGFR1PDGFRBAURKA | |
| SCHEMBL5407511 | 0.84 | SRC (0.73) | KDRFGFR1PDGFRBAURKAAURKB | |
| SCHEMBL29689641 | 0.83 | SRC (0.74) | METKDRFGFR1PDGFRBSRC | |
| SCHEMBL5414900 | 0.82 | SRC (0.75) | KDRFGFR1PDGFRBAURKAAURKB | |
| SCHEMBL5417729 | 0.82 | MET (0.66) | METKDRFGFR1PDGFRBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | claimed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | claimed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | MET 2590/4885KDR 1657/4885FGFR1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.